Abilify nudges $4bn US sales landmark for Otsuka
This article was originally published in Scrip
Executive Summary
Otsuka Holdings has reported a solid set of results for the fiscal year ended 31 March, driven again by international and US growth for its flagship product Abilify (aripiprazole).